Bio-Techne, Nonangen enter into agreement for Oncuria

By LabPulse.com staff writers

May 13, 2022 -- Bio-Techne and Nonagen Bioscience recently entered into an agreement for Bio-Techne's R&D Systems unit to exclusively manufacture Nonagen’s Oncuria bladder cancer diagnostic panel using xMap Luminex technology.

The companies said they are targeting the last quarter of calendar year 2022 to make Oncuria available as a laboratory-developed test.

The U.S. Food and Drug Administration gave Oncuria a breakthrough device designation in 2021 for predicting response to Bacillus Calmette-Guérin therapy, a first-line treatment for bladder cancer.

Bio-Techne touts study with ExoDx prostate test
Bio-Techne is touting a new clinical study that indicates that its exosome-based, noninvasive urine prostate test, ExoDx Prostate test (EPI), correlates...
Nonagen's Oncuria granted FDA designation
The U.S. Food and Drug Administration (FDA) has designated the Oncuria noninvasive bladder cancer test from Nonagen Bioscience as a breakthrough device.
Bio-Techne launches multiplex spatial genomics assay
Bio-Techne has expanded its RNAscope in situ hybridization technology portfolio with the release of the new RNAscope HiPlex V2 assay for formalin-fixed,...
Bio-Techne teams up with Leica to bring RNAscope to Europe
Global life sciences firm Bio-Techne and pathology workflow software developer Leica Biosystems have launched Bio-Techne's RNAscope in situ hybridization...
Bio-Techne's prostate cancer test lands FDA breakthrough status
Bio-Techne's ExoDx Prostate IntelliScore liquid biopsy test for spotting aggressive prostate cancers has received the U.S. Food and Drug Administration's...

Copyright © 2022 LabPulse.com

Last Updated 5/13/2022 1:25:47 PM